The presence of PAI-1 4G/5G and ACE DD genotypes increases the risk of early-stage AVF thrombosis in hemodialysis patients

Renal Failure

Volumn 33, Issue 2, 2011, Pages 169-175

  Güngör, Yahya ^a   Kayataş, Mansur ^a   Yildiz, Gürsel ^a   Özdemir, Öztürk ^a   Candan, Ferhan ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

ACE gene polymorphism; arteriovenous fistula; hemodialysis; PAI 1 4G 5G; thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANGIOTENSIN RECEPTOR ANTAGONIST; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FIBRINOGEN BETA; FIBRINOLYTIC FACTOR; GLYCOPROTEIN IIIA; HOMOCYSTEINE; HUMAN PLATELET ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTERIOVENOUS FISTULA; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HEMODIALYSIS PATIENT; HUMAN; MALE; PRIORITY JOURNAL; THROMBOSIS;

ADULT; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RENAL DIALYSIS; THROMBOSIS;

EID: 79951967022     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.552151     Document Type: Article

References (47)

1. Smits J, van der Linden J, Blankestijn PJ, Rabelink TJ. Coagulation and hemodialysis access thrombosis. Nephrol Dial Transplant. 2000;15:1755-1760.
2. US Renal Data System. Excerpts from the USRDS 2003 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42:S1-S230.
3. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523-535.
4. Schwab SJ. Vascular access for hemodialysis. Kidney Int. 1999;55:2078-2090. (Pubitemid 29198003)
5. LeSae CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. Am Coll Surg. 1999;189:73-81. (Pubitemid 29307745)
6. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001;37:970-980. (Pubitemid 32436569)
7. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
8. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197-205.
9. Wiwanitkit V. Angiotensin-converting enzyme gene polymorphism: I and D alleles from some different countries. Clin Appl Thromb Hemost. 2004;10(2):179-182. (Pubitemid 38490087)
10. Kohler HP, Grant PJ. Mechanisms of disease: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1801-1972.
11. Eriksson P, Kalling B, van't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851-1855.
12. Mansfield MW, Stikland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin dependent diabetes. Thromb Hemost. 1995;74:1032-1034.
13. Ikegaya N, Yamamoto T, Takeshita A, et al. Elevated erythropoietin receptor and transforming growth factor-1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol. 2000;11:928-935. (Pubitemid 30241728)
14. Aznar J, Estelles A, Tormo G, et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 1988;59:535-541.
15. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
16. Kim DK, Kim JW, Kim S, et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 1997;17:3242-3247. (Pubitemid 28016084)
17. Van der Sman-de Beer F, Verhagen C, Rombach SM, et al. ACE I/D polymorphism is associated with mortality in a cohort study of patients starting with dialysis. Kidney Int. 2005;68:2237-2243. (Pubitemid 43117799)
18. So WY, Ma RC, Ozaki R, et al. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients: Interaction with ACE insertion/deletion polymorphism. Kidney Int. 2006;69:1438-1443.
19. Ishimitsu T, Hosoya K, Matsuoka H. The deletion allele of angiotensin-converting enzyme gene polymorphism as a cardiovascular risk factor in patients undergoing long-term hemodialysis. Ann Intern Med. 2000;133:924.
20. Paulson WD. Prediction of hemodialysis synthetic graft thrombosis: Can we identify factors that impair validity of the dysfunction hypothesis? Am J Kidney Dis. 2000;35:973-975. (Pubitemid 30238215)
21. Philipp CS, Dilley A, Saidi P, et al. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Hemost. 1998;80:869-873. (Pubitemid 28556683)
22. Koppel H, Renner W, Gugl A, et al. The angiotensin-converting enzyme insertion/deletion polymorphism is not related to venous thrombosis. Thromb Hemost. 2004;91:76-79. (Pubitemid 38111223)
23. Dilley A, Austin H, Hooper WC, et al. Relation of three genetic traits to venous thrombosis in an African-American population. Am J Epidemiol. 1998;147:30-35. (Pubitemid 28034609)
24. Gonzales Ordonez AJ, Fernandez Carreira JM, Medina Rodriguez JM, et al. Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene. Blood Coagul Fibrinolysis. 2000;11(5):485-490. (Pubitemid 30618528)
25. Makris TK, Stavroulakis GA, Dafni UG, et al. ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension. Am Heart J. 2000;140:760-765.
26. Jackson A, Brown K, Langdown J, Luddington R, Baglin T. Effect of the angiotensin-converting enzyme gene deletion polymorphism on the risk of venous thromboembolism. Br J Hematol. 2000;111:562-564.
27. Isbir CS, Akgun S, Yilmaz H, et al. Is there a role of angiotensin-converting enzyme gene polymorphism in the failure of arteriovenous femoral shunts for hemodialysis? Ann Vasc Surg. 2001;15:443-446. (Pubitemid 32768998)
28. Baek SH, Kye YH, Ahn SH. Role of ACE gene polymorphism on failure of arteriovenous fistula for maintenance of hemodialysis. Korean J Nephrol. 2003;22(6):664-670.
29. Gradzki R, Dhingra RK, Port FK, Roys E, Weitzel WF, Messana JM. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis. 2001;38:1240-1244. (Pubitemid 34193109)
30. Paulson WD, Ram SJ, Faiyaz R, Caldito GC, Atray NK. Association between blood pressure, ultrafiltration, and hemodialysis graft thrombosis: A multivariable logistic regression analysis. Am J Kidney Dis. 2002;40:769-776.
31. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2002;40:1255-1263. (Pubitemid 35403138)
32. Heine GH, Ulrich C, Kohler H, Girndt M. Is AV fistula patency associated with angiotensin-converting enzyme (ACE) polymorphism and ACE inhibitor intake? Am J Nephrol. 2004;24:461-468. (Pubitemid 39279390)
33. Brophy DF, Bukaveckas BL, Ferreira-Gonzalez A, Archer KJ, Martin EJ, Gehr TW. A pilot study of genetic polymorphism and hemodialysis vascular access thrombosis. Hemodial Int. 2009;13:19-26.
34. Moon JY, Jeong KH, Paik SS, et al. Arteriovenous fistula patency associated with angiotensin-converting enzyme I/D polymorphism and ACE inhibition or AT1 receptor blockade. Nephron Clin Pract. 2009;111:c110-c116.
35. Tomura S, Nakamura Y, Doi M, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1996;27(6):848-854. (Pubitemid 26169038)
36. Stegnar M, Uhrin P, Peternel P, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism. Thromb Hemost. 1998;79(5):975-979. (Pubitemid 28224735)
37. Yilmaz E, Akar E, Akar N. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thromboembolic patients with and without prothrombin 20210 G-A. Turk J Hematol. 2004;21(2):83-86. (Pubitemid 38931399)
38. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
39. Akar N, Yilmaz E, Akar E, et al. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV 1691 G-A. Thromb Res. 2000;97:227-230. (Pubitemid 30069711)
40. Lazo-Langer A, Knoll AG, Wells SP, Carson N, Rodger AM. The risk of dialysis access thrombosis is related to the transforming growth factor-beta 1 production haplotype and is modified by polymorphism in the plasminogen activator inhibitor-type 1 gene. Blood. 2006;108:4052-4058. (Pubitemid 44913274)
41. Fukasawa M, Matsushita K, Kamiyama M, et al. The methylenetetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis. 2003;41:637-642. (Pubitemid 36278381)
42. Girndt M, Heine GH, Ulrich C, Köhler H, DialGene Consortium. Gene polymorphism association studies in dialysis: Vascular access. Semin Dial. 2007;2(1):63-67.
43. Bremer C, Schaefer RM. Heterozygosity for factor V Leiden in a hemodialysis patient with recurrent shunt thrombosis. Nephrol Dial Transplant. 1997;12:1775-1776. (Pubitemid 27346326)
44. Atac B, Yakupoglu U, Ozbek N, Ozdemir FN, Bilgin N. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplant Proc. 2002;34:2030-2032. (Pubitemid 35299652)
45. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J. 2003;146:948-957. (Pubitemid 37500767)
46. Akman B, Afsar B, Ataç FB, et al. Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list. Transplant Proc. 2006;38:413-415.
47. Knoll AG, Wells SP, Young D, et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol. 2005;16:1108-1114. (Pubitemid 41710322)